U.S. pharma raises alarm over Trump’s proposed measures against Chinese drugs; China clarifies the type of employees to be bound by non-compete clauses; and Some stablecoin issuers complain that Hong Kong’s regime is too stringent.
With innovation and technological advancement come more complex legal challenges for companies operating across borders. Ruby Chan and Dr Isabella Liu of Baker McKenzie, and Aggie Liu and Cassidy Guo of FenXun, examine the key considerations, best practices, and frequently asked questions for Chinese businesses expanding into the U.S. market
Shanghai puts forward measures to boost foreign-advice business of Chinese law firms; JP Morgan and Bank of America subpoenaed by Congress over CATL IPO; and Nasdaq to require Chinese companies to raise $25 million in IPOs.
Proposed AI Ethics rules will require ethical committees in institutions; Japanese brand Muji’s two-decades old trademark dispute ends in defeat; and China steps up Belt and Road investment as Western trade barriers rise.
The first commercial AI application case in Zhejiang province defines legal limits on generative tools; CFIUS blocked more transactions last year than in previous years amid rising China tensions; and Fintech companies rush to raise equity for stablecoin activity in Hong Kong.
In the first part of a series of articles, Jianwei (Jerry) Fang, Ke Dong, and Haoyi Sun of Zhong Lun Law Firm outline the general jurisdiction rules governing foreign-related civil litigation in China under the 2024 Civil Procedure Law, and explain the statutory framework, key jurisdictional bases, and procedural considerations that foreign companies and in-house counsel need to understand when facing potential lawsuits in Chinese courts
Hainan launches pilot program expanding financial products access to foreigners; Chinese companies reconsider pivot to Southeast Asia as region targeted by U.S. tariffs; and Chinese regulator puts U.S. outbound investments on hold.
FRAND ruling undercuts London’s global ambitions as Samsung’s U.K. win against ZTE risks backfiring in Germany; U.S. consultancy giant asks staff to pause generative AI-related consultancy work in China; and U.S. toymakers diversify away from China amid tariff challenges
The CSRC has not approved U.S. IPOs since April despite a small-cap listing rebound earlier; New arbitration rules emphasize party consent, tribunal independence, and risk management in AI use; and Record-high investments in Belt and Road Initiative driven by strategic sectors.
China rolls out tax breaks for foreign investors reinvesting profits locally; China remains key private equity market but firms are starting to diversify investments; U.S. Congressional bill that targets Chinese AI tools like Deepseek has bipartisan support
